Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Redx Pharma said a poster related to its treatment for the rare lung disease idiopathic pulmonary fibrosis would be presented at a key conference in Madrid.
The poster, for the treatment RXC006, would be presented at the European Respiratory Society International Congress 2019, from 28 September to 2 October.
RXC006 had successfully progressed into manufacturing scale-up and toxicity studies.
The company is aiming to take it into the clinic during the second half of 2020.
At 9:44am: (LON:REDX) Redx Pharma Plc share price was 0p at 8.5p